CVT-301 for Parkinson's disease: dose and effect size issues
The addition of a dopamine agonist, amine oxidase (flavin-containing) B inhibitor, or catechol-O-methyltransferase inhibitor partly reduces daily duration of off episodes, but some patients remain impaired to a point that justifies the use of complex, aggressive, expensive, and inconvenient device-b...
Gespeichert in:
| Veröffentlicht in: | Lancet neurology 2019-02, Vol.18 (2), p.128-130 |
|---|---|
| 1. Verfasser: | |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 130 |
|---|---|
| container_issue | 2 |
| container_start_page | 128 |
| container_title | Lancet neurology |
| container_volume | 18 |
| creator | Rascol, Olivier |
| description | The addition of a dopamine agonist, amine oxidase (flavin-containing) B inhibitor, or catechol-O-methyltransferase inhibitor partly reduces daily duration of off episodes, but some patients remain impaired to a point that justifies the use of complex, aggressive, expensive, and inconvenient device-based therapies. [...]safer, cheaper, and more potent and convenient treatments are needed. Many patients wake up in an off state and must wait up to 60 min or longer before feeling the beneficial effects of their first oral LD-DCI dose. [...]inhaling CVT-301 at such time seems appealing. Post-hoc analyses of off-time responders rather than UPDRS responders might facilitate understanding of the specific target population. [...]CVT-301 should be compared with apomorphine subcutaneous injections, which significantly improve UPDRS scores by 10–20 units within 20 min after administration.10–12 Inhaling a drug is more convenient that using a penjet. |
| doi_str_mv | 10.1016/S1474-4422(18)30496-4 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_hal_p</sourceid><recordid>TN_cdi_hal_primary_oai_HAL_hal_03486387v1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1474442218304964</els_id><sourcerecordid>2168123834</sourcerecordid><originalsourceid>FETCH-LOGICAL-c474t-82eb8f789b36011d48e882a547793e4925db72b64e2adf9494f64c1d2872e2e43</originalsourceid><addsrcrecordid>eNqFkU9PGzEQxa2KqtDARyhaqQfgsMV_Jl5vhYSiqAWkSEUCerW861lhmqypJ0Gin75eEnLgwsnW6Dfz3rxh7Ivg3wQX-vRGQAUlgJTHwpwoDrUu4QPb25T1eGf7l3KXfSZ64FwKMOIT21Vca6U532Nn09-3peKi6GIqrl36E3qK_REVPhA6wu-Fj4SF632BXYftsqDwD4tAtELaZx87Nyc82Lwjdvfzx-30spz9uriaTmZlmw0sSyOxMV1l6iZrCuHBoDHSjaGqaoVQy7FvKtloQOl8V0MNnYZWeGkqiRJBjdjJeu69m9vHFBYuPdvogr2czOxQ4wqMVqZ6Epk9XrOPKf7NHpd2EajF-dz1GFdkpciiNZiaZ_TrG_QhrlKfN8mUNkIqowbx8ZpqUyRK2G0dCG6HU9iXU9ghZyuMfTmFHfoON9NXzQL9tus1-wycrwHM0T0FTJbagH2LPqQctPUxvCPxH3qPk3Q</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2168123834</pqid></control><display><type>article</type><title>CVT-301 for Parkinson's disease: dose and effect size issues</title><source>Elsevier ScienceDirect Journals</source><source>ProQuest Central UK/Ireland</source><creator>Rascol, Olivier</creator><creatorcontrib>Rascol, Olivier</creatorcontrib><description>The addition of a dopamine agonist, amine oxidase (flavin-containing) B inhibitor, or catechol-O-methyltransferase inhibitor partly reduces daily duration of off episodes, but some patients remain impaired to a point that justifies the use of complex, aggressive, expensive, and inconvenient device-based therapies. [...]safer, cheaper, and more potent and convenient treatments are needed. Many patients wake up in an off state and must wait up to 60 min or longer before feeling the beneficial effects of their first oral LD-DCI dose. [...]inhaling CVT-301 at such time seems appealing. Post-hoc analyses of off-time responders rather than UPDRS responders might facilitate understanding of the specific target population. [...]CVT-301 should be compared with apomorphine subcutaneous injections, which significantly improve UPDRS scores by 10–20 units within 20 min after administration.10–12 Inhaling a drug is more convenient that using a penjet.</description><identifier>ISSN: 1474-4422</identifier><identifier>EISSN: 1474-4465</identifier><identifier>DOI: 10.1016/S1474-4422(18)30496-4</identifier><identifier>PMID: 30663600</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Amine oxidase (flavin-containing) ; Apomorphine ; Catechol ; Catechol O-methyltransferase ; Diaries ; Dopamine ; Drug dosages ; Flavin ; Life Sciences ; Methyltransferase ; Movement disorders ; Neurodegenerative diseases ; Parkinson's disease</subject><ispartof>Lancet neurology, 2019-02, Vol.18 (2), p.128-130</ispartof><rights>2019 Elsevier Ltd</rights><rights>Copyright Elsevier Limited Feb 2019</rights><rights>Attribution - NonCommercial</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c474t-82eb8f789b36011d48e882a547793e4925db72b64e2adf9494f64c1d2872e2e43</citedby><cites>FETCH-LOGICAL-c474t-82eb8f789b36011d48e882a547793e4925db72b64e2adf9494f64c1d2872e2e43</cites><orcidid>0000-0002-1410-6397</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.proquest.com/docview/2168123834?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>230,314,778,782,883,3539,27907,27908,45978,64366,64368,64370,72220</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30663600$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://hal.science/hal-03486387$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>Rascol, Olivier</creatorcontrib><title>CVT-301 for Parkinson's disease: dose and effect size issues</title><title>Lancet neurology</title><addtitle>Lancet Neurol</addtitle><description>The addition of a dopamine agonist, amine oxidase (flavin-containing) B inhibitor, or catechol-O-methyltransferase inhibitor partly reduces daily duration of off episodes, but some patients remain impaired to a point that justifies the use of complex, aggressive, expensive, and inconvenient device-based therapies. [...]safer, cheaper, and more potent and convenient treatments are needed. Many patients wake up in an off state and must wait up to 60 min or longer before feeling the beneficial effects of their first oral LD-DCI dose. [...]inhaling CVT-301 at such time seems appealing. Post-hoc analyses of off-time responders rather than UPDRS responders might facilitate understanding of the specific target population. [...]CVT-301 should be compared with apomorphine subcutaneous injections, which significantly improve UPDRS scores by 10–20 units within 20 min after administration.10–12 Inhaling a drug is more convenient that using a penjet.</description><subject>Amine oxidase (flavin-containing)</subject><subject>Apomorphine</subject><subject>Catechol</subject><subject>Catechol O-methyltransferase</subject><subject>Diaries</subject><subject>Dopamine</subject><subject>Drug dosages</subject><subject>Flavin</subject><subject>Life Sciences</subject><subject>Methyltransferase</subject><subject>Movement disorders</subject><subject>Neurodegenerative diseases</subject><subject>Parkinson's disease</subject><issn>1474-4422</issn><issn>1474-4465</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNqFkU9PGzEQxa2KqtDARyhaqQfgsMV_Jl5vhYSiqAWkSEUCerW861lhmqypJ0Gin75eEnLgwsnW6Dfz3rxh7Ivg3wQX-vRGQAUlgJTHwpwoDrUu4QPb25T1eGf7l3KXfSZ64FwKMOIT21Vca6U532Nn09-3peKi6GIqrl36E3qK_REVPhA6wu-Fj4SF632BXYftsqDwD4tAtELaZx87Nyc82Lwjdvfzx-30spz9uriaTmZlmw0sSyOxMV1l6iZrCuHBoDHSjaGqaoVQy7FvKtloQOl8V0MNnYZWeGkqiRJBjdjJeu69m9vHFBYuPdvogr2czOxQ4wqMVqZ6Epk9XrOPKf7NHpd2EajF-dz1GFdkpciiNZiaZ_TrG_QhrlKfN8mUNkIqowbx8ZpqUyRK2G0dCG6HU9iXU9ghZyuMfTmFHfoON9NXzQL9tus1-wycrwHM0T0FTJbagH2LPqQctPUxvCPxH3qPk3Q</recordid><startdate>20190201</startdate><enddate>20190201</enddate><creator>Rascol, Olivier</creator><general>Elsevier Ltd</general><general>Elsevier Limited</general><general>Elsevier</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>0TZ</scope><scope>3V.</scope><scope>7RV</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88G</scope><scope>8AO</scope><scope>8C2</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>M2M</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>7X8</scope><scope>1XC</scope><scope>VOOES</scope><orcidid>https://orcid.org/0000-0002-1410-6397</orcidid></search><sort><creationdate>20190201</creationdate><title>CVT-301 for Parkinson's disease: dose and effect size issues</title><author>Rascol, Olivier</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c474t-82eb8f789b36011d48e882a547793e4925db72b64e2adf9494f64c1d2872e2e43</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Amine oxidase (flavin-containing)</topic><topic>Apomorphine</topic><topic>Catechol</topic><topic>Catechol O-methyltransferase</topic><topic>Diaries</topic><topic>Dopamine</topic><topic>Drug dosages</topic><topic>Flavin</topic><topic>Life Sciences</topic><topic>Methyltransferase</topic><topic>Movement disorders</topic><topic>Neurodegenerative diseases</topic><topic>Parkinson's disease</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Rascol, Olivier</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Pharma and Biotech Premium PRO</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Neurosciences Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Psychology Database (Alumni)</collection><collection>ProQuest Pharma Collection</collection><collection>Lancet Titles</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest Psychology</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>Hyper Article en Ligne (HAL)</collection><collection>Hyper Article en Ligne (HAL) (Open Access)</collection><jtitle>Lancet neurology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Rascol, Olivier</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>CVT-301 for Parkinson's disease: dose and effect size issues</atitle><jtitle>Lancet neurology</jtitle><addtitle>Lancet Neurol</addtitle><date>2019-02-01</date><risdate>2019</risdate><volume>18</volume><issue>2</issue><spage>128</spage><epage>130</epage><pages>128-130</pages><issn>1474-4422</issn><eissn>1474-4465</eissn><abstract>The addition of a dopamine agonist, amine oxidase (flavin-containing) B inhibitor, or catechol-O-methyltransferase inhibitor partly reduces daily duration of off episodes, but some patients remain impaired to a point that justifies the use of complex, aggressive, expensive, and inconvenient device-based therapies. [...]safer, cheaper, and more potent and convenient treatments are needed. Many patients wake up in an off state and must wait up to 60 min or longer before feeling the beneficial effects of their first oral LD-DCI dose. [...]inhaling CVT-301 at such time seems appealing. Post-hoc analyses of off-time responders rather than UPDRS responders might facilitate understanding of the specific target population. [...]CVT-301 should be compared with apomorphine subcutaneous injections, which significantly improve UPDRS scores by 10–20 units within 20 min after administration.10–12 Inhaling a drug is more convenient that using a penjet.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>30663600</pmid><doi>10.1016/S1474-4422(18)30496-4</doi><tpages>3</tpages><orcidid>https://orcid.org/0000-0002-1410-6397</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1474-4422 |
| ispartof | Lancet neurology, 2019-02, Vol.18 (2), p.128-130 |
| issn | 1474-4422 1474-4465 |
| language | eng |
| recordid | cdi_hal_primary_oai_HAL_hal_03486387v1 |
| source | Elsevier ScienceDirect Journals; ProQuest Central UK/Ireland |
| subjects | Amine oxidase (flavin-containing) Apomorphine Catechol Catechol O-methyltransferase Diaries Dopamine Drug dosages Flavin Life Sciences Methyltransferase Movement disorders Neurodegenerative diseases Parkinson's disease |
| title | CVT-301 for Parkinson's disease: dose and effect size issues |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-16T19%3A24%3A25IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_hal_p&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=CVT-301%20for%20Parkinson's%20disease:%20dose%20and%20effect%20size%20issues&rft.jtitle=Lancet%20neurology&rft.au=Rascol,%20Olivier&rft.date=2019-02-01&rft.volume=18&rft.issue=2&rft.spage=128&rft.epage=130&rft.pages=128-130&rft.issn=1474-4422&rft.eissn=1474-4465&rft_id=info:doi/10.1016/S1474-4422(18)30496-4&rft_dat=%3Cproquest_hal_p%3E2168123834%3C/proquest_hal_p%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2168123834&rft_id=info:pmid/30663600&rft_els_id=S1474442218304964&rfr_iscdi=true |